Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 4 , Pages 583-589 , August 2010

Hepatoma-targeted gene delivery using a tumor cell–specific gene regulation system combined with a human liver cell–specific bionanocapsule

  • Jeong-Hun Kang, PhD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • These authors contributed equally to this work.
    • ,
  • Jun Oishi, PhD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • These authors contributed equally to this work.
    • ,
  • Jong-Hwan Kim, PhD

      Affiliations

    • Faculty of Education, Nagasaki University, Nagasaki, Japan
    • ,
  • Moeko Ijuin, MD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • ,
  • Riki Toita, MD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • ,
  • Byungdug Jun, PhD

      Affiliations

    • Faculty of Education, Nagasaki University, Nagasaki, Japan
    • ,
  • Daisuke Asai, PhD

      Affiliations

    • Department of Microbiology, St. Marianna University School of Medicine, Kawasaki, Japan
    • ,
  • Takeshi Mori, PhD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • ,
  • Takuro Niidome, PhD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • Center for Future Chemistry, Kyushu University, Fukuoka, Japan
    • ,
  • Katsuyuki Tanizawa, PhD

      Affiliations

    • Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan
    • ,
  • Shun'ichi Kuroda, PhD

      Affiliations

    • Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan
    • ,
  • Yoshiki Katayama, PhD

      Affiliations

    • Department of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan
    • Graduate School of Systems Life Sciences, Kyushu University, Fukuoka, Japan
    • Center for Future Chemistry, Kyushu University, Fukuoka, Japan
    • Corresponding Author InformationCorresponding author: Department of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-Ku, Fukuoka 819-0395, Japan.

Received 4 July 2009 ,Accepted 15 January 2010.

References 

  1. Berrino F, De Angelis R, Sant M, Rosso S, Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: resutls of the EUROCARE-4 study. Lancet Oncol. 2007;8:773–783
  2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  3. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord. 2003;3:8–24
  4. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–1327
  5. Herr I, Schemmer P, Büchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology. 2008;46:266–274
  6. Hui KM. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr Opin Mol Ther. 2007;9:378–384
  7. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866–3884
  8. Calvisi DF, Pascale RM, Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials. 2007;2:217–236
  9. Riki T, Kang JH, Kim JH, Tomiyama T, Mori T, Niidome T, et al. Protein kinase Cα-specific peptide substrate graft-type copolymer for cancer cell-specific gene regulation systems. J Control Release. 2009;139:133–139
  10. Kawamura K, Oishi J, Kang JH, Kodama K, Sonoda T, Murata M, et al. Intracellular signal-responsive gene carrier for cell-specific gene expression. Biomacromolecules. 2005;6:908–913
  11. Oishi J, Kawamura K, Kang JH, Kodama K, Sonoda T, Murata M, et al. An intracellular kinase signal-responsible gene-carrier for cell specific gene therapy. J Control Release. 2006;110:431–436
  12. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–1934
  13. Cohen P. Protein kinases—the major drug targets of the twenty-first century?. Nat Rev Drug Discov. 2002;1:309–315
  14. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr Cancer Drug Targets. 2004;4:125–146
  15. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs. 2001;10:2117–2140
  16. O'Brian CA, Chu F, Bornmann WG, Maxwell DS. Protein kinase Cα and ɛ small-molecule targeted therapeutics: a new roadmap to two holy grails in drug discovery?. Expert Rev Anticancer Ther. 2006;6:175–186
  17. Kang JH, Asai D, Yamada S, Toita R, Oishi J, Mori T, et al. A short peptide is a protein kinase C (PKC) α-specific substrate. Proteomics. 2008;8:2006–2011
  18. Kang JH, Asai D, Kim JH, Mori T, Toita R, Tomiyama T, et al. Design of polymer carriers for cancer-specific gene targeting: utilization of abnormal protein kinase Cα activation in cancer cells. J Am Chem Soc. 2008;130:14906–14907
  19. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MKL, VandenDriessche T, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003;21:885–890
  20. Jung J, Tatematsu K, Matsuzaki T, Okajima T, Ueda M, Kondo A, et al. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J Control Release. 2008;125:255–264
  21. Kasuya T, Jung J, Kadoya H, Matsuzaki T, Tatematshu K, Okajima T, et al. In vivo delivery of bionanocapsules displaying Phaseolus vulgaris agglutinin-L4 isolectin to malignant tumors overexpressing N-acetylglucosaminyltransferase V. Hum Gene Ther. 2008;19:887–895
  22. Cook PF, Neville ME, Vrana KE, Hartl FT, Roskoski R. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry. 1982;21:5794–5799
  23. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol. 2006;7:261–276
  24. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev. 2002;54:37–51
  25. Boyault S, Rickman D, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and new therapeutic targets. Hepatology. 2007;45:42–52
  26. Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des. 2007;13:3279–3287

 This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

PII: S1549-9634(10)00014-6

doi: 10.1016/j.nano.2010.01.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 4 , Pages 583-589 , August 2010

Article Tools

* Image Usage & Resolution